Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxervate in neurotrophic keratitis (China real‑world PK/IV study)
CTR20220066Phase 4Completed
- Sponsor
- Dompé
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cenegermin in neurotrophic keratitis (NK), sponsored by Dompé. Primary endpoint: Complete healing of PED or corneal ulcer at week 8. Started Jan 2022; status: completed.
02
Drugs
cenegermin
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on CTR20220066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220066.